


MilliporeSigma invests €290 M in new biosafety testing facility in US

09 October 2024 | News

Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building



MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA. Biosafety testing and analytical development are fundamental components of drug development and commercialisation for traditional and novel modalities. Global demand for these services is growing at a double-digit rate.

The 23,000-square-meter facility will house biosafety testing, analytical development, and cell banking manufacturing services. It consolidates labs currently spread across four buildings into a single facility. This will increase collaboration between scientists and enable a higher level of automation and digitalization to increase Right First Time (RFT).

The Life Science business of Merck KGaA, Darmstadt, Germany, has made significant investments over the last five years to expand its biosafety testing capabilities for clients across the globe. The company's global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.

The new site will feature advanced testing capabilities, including a rapid methods package, designed to accelerate virus testing of bulk harvest material. This package is the first to include the Blazar CHO Animal Origin Free (AOF) panel, a targeted molecular method for detecting virus families. By combining the Blazar CHO AOF panel with assays for mycoplasma, sterility, and retrovirus-like particle detection, test results can be obtained in just 14 days, compared to 35 days with traditional assay methods.